Roche (RHHBY,RO.SW,ROG.SW) announced the launch of its Liver Disease Panel, a suite of certified algorithms including the CE-marked algorithm LiverPRO, to support better-informed clinical decisions, from timely fibrosis risk identification, to the surveillance of liver cancer.
The Liver Disease Panel represents Roche's first digital portfolio of biomarker and digital algorithm solutions designed to support care across key stages of the chronic liver disease pathway. Through a collaboration with Evido, Liver Disease Panel includes LiverPRO, an algorithm that adapts to existing patient data — requiring only age and and a minimum of three out of nine common blood-based biomarkers to assess the risk of liver fibrosis.
Matt Sause, CEO Roche Diagnostics, said: "With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health."
Shares of Roche are trading at 329.70 Swiss francs, down 0.45%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.